Le plus ca change: Why we need better biomarkers to predict outcomes in ulcerative colitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 7, 2011, Pages 1085-1086

  Andrews, Jane M ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOSALICYLIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CORTICOSTEROID; HEMOGLOBIN; MERCAPTOPURINE; PREDNISOLONE;

ALBUMIN BLOOD LEVEL; CORTICOSTEROID THERAPY; EDITORIAL; ERYTHROCYTE SEDIMENTATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KOREA; MAINTENANCE THERAPY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 79958822013     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06754.x     Document Type: Editorial

References (12)

1. Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J. Gastroenterol. Hepatol. 2011; 26: 1114-22.
2. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
3. Travis S, Satsangi J, Lemann M. Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut 2011; 60: 3-9.
4. Haritunians T, Taylor KD, Targan SR etal. Genetic predictors of medically refractory ulcerative colitis. Inflamm. Bowel Dis. 2010; 16: 1830-40.
5. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
6. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 940-87.
7. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 2006; 23: 577-85.
8. Rutter M, Saunders B, Wilkinson K etal. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-9.
9. Ardizzone S, Cassinotti A, Duca P etal. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin. Gastroenterol. Hepatol. 2010 (in press).
10. Modigliani R, Mary JY, Simon JF etal. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-18.
11. Teshima C, Fedorak RN. Are there differences in type, dosage, and method of administration for the systemic steroids in IBD treatment? Inflamm. Bowel Dis. 2008; 14 (Suppl. 2): S216-18.
12. Bebb JR, Scott BB. How effective are the usual treatments for ulcerative colitis? Aliment. Pharmacol. Ther. 2004; 20: 143-9.